Source link : https://www.newshealth.biz/health-news/daiichi-sankyo-mercks-cancer-drug-meets-main-goal-in-late-stage-trial/
(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer. The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated with chemotherapy, the companies said. The drug belongs […]
Author : News Health
Publish date : 2024-09-17 10:11:03
Copyright for syndicated content belongs to the linked Source.